Using randomized trial data and a novel evidence synthesis approach, our analyses indicate that comparisons of different RAS blockers showed similar effects of ACE inhibitors and ARBs on major cardiovascular and renal outcomes in adults with diabetes mellitus. The gene discussed is ACE; the disease is diabetes mellitus.